Emerging evidence demonstrates that GLP-1 receptors are expressed in Type II taste cells, where they modulate sweet sensitivity through the G-gustducin/TRPM5 pathway, and downregulate T1R2/T1R3 expression and ATP release (1, 15)
It is important to rotate injection sites (abdomen, thigh, or upper arm) to minimise these reactions
K., Friis-Hansen, L., Hilsted, L., & Feldt-Rasmussen, U
Most protocols begin with lower doses and increase gradually
A 2023 New England Journal of Medicine trial found that 25% of tirzepatide patients reported nausea at peak doses, compared to 20% of semaglutide users, though both rates declined over time